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Bottromycins were originally isolated from the fermentation
broth of Streptomyces bottropensis in the late 1950s and
described as peptidic natural products with antibacterial
activity against Gram-positive pathogens.1,2 A series of mecha-
nism of action (MoA) studies revealed that bottromycins inhibit
protein synthesis by binding to the aminoacyl-tRNA binding site
(A-site) of the prokaryotic 50S ribosome.3–5 The bottromycin
target site is currently not addressed by any antibiotic used in
the clinic, which makes cross-resistance unlikely. As a result,
bottromycins are effective against the problematic human
pathogens methicillin-resistant Staphylococcus aureus (MRSA)
and vancomycin-resistant Enterococci (VRE).
The chemical structure of bottromycins proved very difficult
to elucidate and consequently underwent several revisions that
ultimately led to the assignment of 1. It showed that bot-
tromycins are highly modied heptapeptides that are
comprised of an N-terminal, four-amino acid macrocycle
formed via a unique amidine linkage, several C-methylated
residues, D-aspartate and a C-terminal thiazole (Fig. 1A). This
structure was conrmed by total synthesis in 2009.10 Shortly
aer the successful total synthesis, several groups reported the
discovery of the bottromycin biosynthetic gene cluster (BGC),
which revealed that they are unusual ribosomally synthesized
and post-translationally modied peptides (RiPPs).6,8,11,12
The emerging RiPP superfamily encompasses highly diverse
molecules with interesting bioactivities.13 The unifying feature
is their biosynthetic logic: a short structural gene is expressed
and yields the precursor peptide, which consists of one or more
core peptide(s) (the eventual natural product(s)) and an N-
terminal leader or C-terminal follower peptide that is impor-
tant for recognition of the precursor peptide by parts of theNat. Prod. Rep.


































































































View Article Onlinebiosynthetic machinery. The post-translational modications
introduced in the core peptide have been reviewed extensively
elsewhere and expand the chemical and structural features far
beyond the 20 canonical amino acids.13,15 These modications
include, but are not limited to, heterocyclisation of Ser/Thr and
Cys residues to oxazolines and thiazolines, oxidation of these
heterocycles to the corresponding azoles, epimerisation of
amino acids to give D-stereocentres, methylation, Ser/Thr/Tyr
prenylation, dehydration, hydroxylation, macrocycle formation
and the formation of new C–C bonds through different chem-
istries. In fact, in some RiPPs such as pyrroloquinoline quinone,
the nal product does not contain any peptide bonds.15 Bot-
tromycins are the only RiPP of bacterial origin that utilises
a follower peptide rather than the canonical leader peptide for
biosynthesis.6,8,11,12
This review aims to cover all aspects of bottromycin research
with a focus on the recent years (2009–2020). We will place
particular emphasis on the total synthesis of bottromycins,
studies conducted to investigate the biosynthesis and produceLaura Franz studied biochem-
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Nat. Prod. Rep.derivatives in vivo and very recent progress on the enzymology of
individual steps involved in bottromycin biosynthesis.2 Discovery, structure elucidation
and activity
In 1955, a new Streptomyces species, Streptomyces bottropensis,
isolated from a soil sample taken in the German town Bottrop,
was reported.16 Its fermentation broth displayed antibiotic
activity and led to the discovery of a new antibiotic, named
bottromycin.1,16 Waisvisz and coworkers were the rst group to
investigate the bottromycin structure and reported that
although bottromycin itself gave a negative ninhydrin test,
hydrolysis of bottromycins gave 7 ninhydrin positive
compounds. Four remained unspecied, but two that could be
identied as glycine and valine.1,17–19 Acetylation of bottromycin
yielded two degradation products, which were further analysed.
This resulted in the identication of two ninhydrin-positive
compounds, a-amino-b-phenylbutyric (MePhe) acid and b-(2-Andrew Truman obtained his
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Staphylococcus aureus (Smith) 0.2 0.8 0.1
Staphylococcus aureus (209 P) 0.1 0.8 0.1
Staphylococcus aureus (BR4) 0.4 0.8 0.4
Staphylococcus aureus (R1) 0.4 1.5 0.4
Staphylococcus aureus (R5) 0.4 1.5 0.4
Staphylococcus aureus (R6) 0.4 1.5 0.2
Micrococcus avus 0.4 1.5 1.5
Bacillus subtilis (PCI 219) 0.06 0.2 0.06
Bacillus cereus (IAM 1729) 0.4 0.8 0.25
Corynebacterium xerosis 0.06 0.2 0.06
Mycobacterium phlei 0.1 1.5 0.1
Mycobacterium 607 25 (25) (12)
Shigella dysenteria 12 25 25
Shigella sonnei 25 >100 50
Salmonella typhosa 50 >100 >100
Salmonella paratyphi 25 6 6
Escherichia coli B 3 25 6
Escherichia coli K12 25 100 50
Klebsiella pneumoniae 602 50 >100 >100
Pseudomonas aeruginosa A3 50 >100 100
Sarcina lutea 0.4 0.8
Proteus vulgaris OX-19 12 100 50
a S. aureus BR4, R1, R5 and R6 are clinical isolates resistant to
antibiotics: BR4 is erythromycin–carbomycin resistant, R1 and R6 are
penicillin-tetracycline resistant.
Fig. 1 Structures of bottromycins. (A) Structural formular of bot-
tromycin A2, B2, C2 and D. (B) NMR structure of bottromycin A2 in
CDCl3. Coloured fragements in (A) represent the identified ninhydrin
positive compounds after hydrolysis of bottromycin during the
structure elucidation process of bottromycin.


































































































View Article Onlinethiazole)-b-alanine methyl ester (thia-b-Ala-OMe)18 as well as the
previously identied glycine and valine.19 Thus, only two of the
unknown hydrolysis products remained obscure. As part of
these studies, a methyl ester moiety was identied and further
analysed: mild alkaline hydrolysis yielded a biologically inactive
bottromycin,17 while re-esterication in methanolic HCl solu-
tion yielded a biologically active compound identical with bot-
tromycin. Esterication with ethanol or n-butyl alcohol
produced less active bottromycin derivatives.17
In 1965, Nakamura and colleagues reported the isolation of
bottromycin from Streptomyces No. 3668-L2.20 They were able to
identify the two remaining unknown ninhydrin-positive
substances from acid hydrolysis as L-b,b-dimethyl-alpha-
aminobutyric acid (tert-leucine, t-Leu) and L-cis-3-methylproline
(MePro).21 Analysis of the isolated antibiotic by thin-layer chro-
matography revealed it to contain a major component, which was
identical to the previously studied bottromycin and designated as
bottromycin A, and two minor components, designated asThis journal is © The Royal Society of Chemistry 2021bottromycin B and C.21,22 Bottromycin B and C are almost identical
to bottromycin A, but contain L-proline (bottromycin B) and L-3,3-
dimethylproline (Me2Pro) (bottromycin C) instead of MePro. Bot-
tromycins B and C are biologically active, but bottromycin B dis-
played 3–4 times less potency than bottromycin A and C (see
Tables 1 and 5).22 Nakamura and colleagues also reported the
recovery of pivalic acid aer hydrolysis of bottromycin beside the 6
previously described compounds.21 Different tests (i.e. van Slyke
test) also suggested the existence of an amidine group in bot-
tromycin in the tetrapeptide moiety.21 It was concluded that the N-
terminus of bottromycins must not be free, because they are
negative in ninhydrin reactions, Edman degradation and Sanger
decomposition.21 The structure (2) that was proposed based on
these data harboured pivalic acid at the N-terminus of the tetra-
peptide (t-Leu, Val, MePro, Gly) (Fig. 2). A subsequent revision of
the structure postulated 1-D1-caproic acid instead of pivalic acid at
the N-terminus.23 Bottromycin with pivalic acid was designated as
bottromycin A1, and bottromycin containing 1-D
1-caproic acid was
designated as bottromycin A2, but synthetic attempts by Yamada
et al. indicated that the proposed structure was incorrect.24
Ten years later, Takita and colleagues proposed a new structure
for bottromycin, based on mass spectrometry and 1H NMR data.25
This cyclic structure of the tetrapeptide was revised by Shipper in
1983,26 who demonstrated that an unusual amidine moiety links
the cyclic tetrapeptide and the linear chain and is formed by
condensation of N-terminal amino group and the backbone amide
carbonyl. In spite of these iterative revisions, and the fact thatNat. Prod. Rep.
Fig. 2 Structure of bottromycin (2) according to Nakamura et al.21


































































































View Article Onlinebottromycin A1 and A2 were actually identical, the designation
bottromycin A2 (as well as B2 and C2) for bottromycin A, B and C
was retained. It took until 2009 before the correct structure of
bottromycin A2 (1a) (see Fig. 1A) was determined by Shimamura
et al. through the total synthesis of bottromycin A2, demonstrating
the D-conguration of the thia-b-Ala-OMe.10 In 2012, Gouda et al.
determined the three-dimensional structure of bottromycin A2 in
CDCl3 based on NMR data.27 In this structure (Fig. 1B) the C-
terminal residues fold back on the macrocycle made by the four
N-terminal amino acids. Hence, the MePro and the thia-b-Ala-
OMe, which are essential for activity, are on one side of the
three-dimensional structure, which suggests an involvement of
this region in target engagement.
Biological data for bottromycins A2–C2 were reported by Naka-
mura et al.22 They determined the minimal growth inhibitory
concentrations (MIC) towards a wide range of bacterial strains
(Table 1). In addition, bottromycin A2 also showed strong inhibi-
tion against mycoplasma (0.001–0.01 mg mL1),2,28 the multidrug-
resistant human pathogens MRSA (1 mg mL1) and VRE (0.5 mg
mL1)2 and Xanthomonas oryzae pv. oryzae KACC 10331, a pathovar
that causes rice bacterial blight,29 which makes bottromycins
potentially interesting for agrochemical use.
Although highly active in vitro, the bottromycins showed no
convincing in vivo efficiency because of their instability in oral
and parenteral administration,30 which is mainly the result of
the lability of the methyl ester under physiological conditions.2
Synthetic approaches to change the methyl ester moiety could
increase plasma stability without decreasing the activity (see
Tables 2–5). In vivo studies using bottromycin derivatised at the
methyl ester moiety displayed in vivo activity against staphylo-
coccal and streptococcal infection in animals,30 and Myco-
plasma gallispetium (pleuropneumonia-like organisms) in
chicken using subcutaneous administration.28,31,32
3 Mechanism of action
In MoA studies, it was demonstrated that bottromycin A2
inhibits protein synthesis,33 which is a common target of anti-
biotics (e.g. aminoglycosides andmacrolides). How bottromycin
inhibits protein synthesis was investigated by different groups,
who came to divergent conclusions.
Tanaka and co-workers were therst group that studied theMoA
of bottromycin and demonstrated the inhibition of protein
biosynthesis in vivo and in vitro.33 The inhibition was reported to be
highly dependent on the base composition.33 They showed thatNat. Prod. Rep.bottromycin inhibits neither aminoacyl-tRNA synthesis nor its
binding to the ribosome.33 The puromycin reaction, which is
regarded as an analogous reaction to the peptide bond formation,
was not signicantly affected by bottromycin A2 in the absence of
guanosine triphosphate (GTP) and G factor. This reaction does not
require GTP or G factor. Addition of GTP and G factor stimulate
translocation of the peptidyl-tRNA from the A- to the P-site. In the
presence of GTP and G factor the puromycin reaction was inhibited
by bottromycin A2.34,35 They concluded from these results that bot-
tromycin A2 interferes with the translocation of peptidyl-tRNA and
movement of mRNA on the ribosomes.35,36 In a cell-free system, it
was determined on which subunit of the ribosome the antibiotic
acts. Examining the inhibitory effect of bottromycin A2 in a protein
synthesising system containing excess of either 30S or 50S ribo-
somal subunit, the excess of 50S over 30S subunit decreased the
inhibitory effect by bottromycin. This effect could not be observed
using an excess of 30S over 50S subunit. From these results it was
concluded that bottromycin interacts with the 50S subunit of the
ribosome.37
Pestka and Brot also examined the effect of bottromycin on
several steps of the protein synthesis.38 They also determined an
effect of bottromycin on the translocation process, using an
oligophenylalanine formation assay. An inhibitory effect was
observed in the absence and presence of G protein and GTP. In
contrast to Tanaka et al., they also observed an effect of bot-
tromycin on peptide bond synthesis using an acetyl-
phenylalanyl-puromycin formation assay.38 As the degree of
inhibition on oligophenylalanine synthesis and the puromycin
reaction were comparable, they suggested that the inhibition of
the peptide bond formation may be the primary action of bot-
tromycin A2.38
The latest studies examining the MoA of bottromycins were
carried out in the early 1980s by Otaka and coworkers.3–5 They
reported that bottromycin interferes with the interaction of
aminoacyl- or peptidyl-tRNA with the A (aminoacyl) site of
ribosomes3,5 and proposed the hypothesis that bottromycin
binds to (or close to) the A site of the ribosome and lowers the
affinity of aminoacyl-, peptidyl-tRNA or puromycin.4,5
The proposed MoA of bottromycin from Otaka and
coworkers is similar to the mechanism of tetracyclines. Tetra-
cyclines block the binding of aminoacyl-tRNAs to the A site of
the ribosome,39 but only bottromycins are able to release bound
tRNA from the A site. While tetracyclines bind to the 30S ribo-
somal subunit,39,40 bottromycins are reported to bind the 50S
subunit of the ribosome.37 The different MoAs and binding sites
between tetracycline and bottromycin are also supported by the
observation that no cross-resistance to the tetracycline-resistant
strains S. aureus R1 and R6 (Table 1) is observed. Other anti-
biotics that act at the A-site can also have different functions,
such as negamycin, which inhibits translocation and stimulates
miscoding.40–42 In the past decade, multiple structures of the
70S ribosome or its subunits in complex with antibiotics have
been determined, which provided insights into their mecha-
nism of action.42,43 Unfortunately, no ribosome–bottromycin
complex structure has been published yet, so our under-
standing of the MoA of bottromycin remains limited.This journal is © The Royal Society of Chemistry 2021


































































































View Article Online4 Synthetic approaches and total
syntheses towards bottromycins
4.1 Synthesis of the unusual amino acids44
Based on the early structure proposals, the rst syntheses of the
unusual amino acid building blocks were reported from themid
1970's on. A rst stereospecic synthesis of (2S,3R)-3-methyl-
proline (MePro) was reported by Titouani et al. in 1980 using
a Hofmann–Löffler–Freitag reaction.45 Herdeis et al. reported
the syntheses of both, the (2S,3S)- and the (2S,3R)-isomer of
MePro from a pyroglutaminol derivate,46 while Karoyan and
Chassaing used a 5-exo trig cyclisation approach to generated
the ve-membered ring.47 Kamenecka et al. developed
a protocol starting from commercially available 3-hydroxy-(S)-
proline using Stille cross coupling chemistry,48 and a stereo-
selective cuprate addition was the key step in the synthesis by
Flamant-Robin et al.49
3,3-Dimethyl-(2S)-proline (Me2Pro) is one of the unusual
amino acids found in bottromycin C2. A rst enantioselective
synthesis was reported by Sharma and Lubell in 1996.50 A
regioselective enolisation of a 4-oxo-proline derivative followed
by alkylation with different alkyl halides allowed the synthesis
of a variety of proline derivatives. Two approaches towards
racemic Me2Pro were described by Medina51 and Bott et al.52
Most investigations focused on the synthesis of (2S,3S)-3-
methylphenylalanine (MePhe) because it also appears in some
other natural products, such as mannopeptimycin53 and the
isoleucyl-tRNA-synthetase inhibitor SB-203208.54 In connection
with one of the rst synthetic studies towards bottromycins,
Kataoka et al. described the synthesis and optical resolution of
MePhe via condensation of racemic 1-bromo-1-phenyl-ethane
with acetaminomalonate.55 Many attempts have been under-
taken to separate the stereoisomers more easily using modern
chromatographic techniques.56–64 Ogawa et al. reported an
enzymatic approach to MePhe,65 while Tsuchihashi et al. used
theMichael addition of malonate onto a chiral vinyl sulfoxide as
a key step.66 Dharanipragada et al.67,68 and Fioravanti et al.69
described the asymmetric syntheses of MePhe using auxiliary-
controlled enolate chemistry, while the groups of Pericas and
Rieva developed a protocol using a Sharpless epoxidation as
a stereo-controlling step.70 O'Donnell et al. reported an acyclic
stereoselective boron alkylation as a key step using a chiral
boron reagent in the presence of cinchona alkaloids,71 while the
group of Turner developed a chemo-enzymatic route towards
enantiomerically pure MePhe derivatives, based on an
oxidation-reduction sequence.72 Ooi et al. described a phase
transfer-catalysed alkylation of a glycinate Schiff base with 1-
bromo-1-phenylethane under the inuence of chiral quaternary
ammonium bromide and 18-crown-6.73 And nally, Zhang et al.
reported a palladium-catalysed C–H functionalisation of C(sp3)–
H bonds using 8-aminoquinoline (AQ) as a directing group,
giving access to fully protected MePhe derivatives.
The unusual C-terminal thiazolyl amino acid thia-b-Ala was
the last one whose conguration was determined. It required
the total synthesis of the bottromycins to establish it deni-
tively. The problem arose from the structure elucidation ofThis journal is © The Royal Society of Chemistry 2021bottromycin. By hydrolysis of the natural product with conc.
HCl, Waisvisz et al. obtained a “sulfur-containing amino acid”,
which unfortunately showed no optical activity.18 Umezawa's
group subsequently obtained an optically active amino acid
([a]18D : +9) by hydrolysing the antibiotic with acetic anhydride.74
To determine the structure of the C-terminal amino acid
Waisvisz prepared racemic thia-b-Ala by addition of hydroxyl-
amine towards b-2-thiazolacrylic acid, unfortunately only with
moderate yield.75
Seto et al. tried to obtain optically active (S)-thia-b-Ala start-
ing from (S)-aspartic acid.75 Thiazole formation was performed
by condensation of the corresponding protected aspartic acid
thioamide with bromoacetaldehyde, but unfortunately, these
derivatives were also optically inactive. Obviously, complete
epimerisation occurred in the thiazole formation step. The
racemic amino acid, however, could be resolved into its enan-
tiomers by treating the Phth-derivative with brucine.49 Aer
cleavage of the Phth-protecting group, the (+)-amino acid, the
constituent of bottromycin, was isolated in pure form. It should
be mentioned that the thia-b-Ala derivatives prepared also lost
their optical activity aer heating under reux in 6 N HCl for
8 h, while the same compounds were stable at room tempera-
ture or under slightly basic conditions, illustrating the cong-
urational lability of these compounds. The only enantioselective
synthesis of enantiomerically pure (S)-and (R)-thia-b-Ala so far
was reported by the groups of Sunazuka and Ōmura,10 taking
advantage of the chiral sulnamide chemistry developed by
Davis and Ellman,76,77 which allowed the synthesis of both
enantiomers in a highly stereoselective fashion.4.2 Synthetic studies towards bottromycins
The total synthesis of bottromycins was adversely affected by
the long-standing erroneous structure proposals for the
compounds, and so far only one total synthesis exists.10,78 It
conrmed that the C-terminal thia-b-Ala is (R)-congured and
not (S)- as originally reported.
While the wrong structural assumptions meant that early
synthetic work could only ever be unsuccessful, signicant
efforts were directed towards the synthesis of the partial struc-
ture of this rather unique peptide. The rst investigations were
already reported by Yamada et al. in 1997.79 Their synthetic
route was based on the linear hexapeptide 2 proposed by
Nakamura et al. (Fig. 2).22,74,80,81
Yamada et al. focused on the synthesis and properties of the
central amidine unit. Several amidines were prepared by
condensation of Cbz-protected amino acid imido esters with
amino acid esters (Scheme 1).24 The desired amidine 3 could be
obtained without problems, but it was impossible to extend the
dipeptides at the C-terminus. On activation, or even on standing
under basic conditions cyclisation occurred to the correspond-
ing imidazolone 4. Therefore, the authors decided to form the
amidine unit of 7 by coupling two model tripeptide fragments,
the tripeptide imido ester 5 and tripeptide 6.24
Interestingly, the pKa of all synthesised amidines (pKa  9.3)
were around 1 pKa higher than in the natural product (8.2),
a rst indication that the structure proposal might not beNat. Prod. Rep.
Scheme 1 Formation of amidine 7.
Scheme 2 Synthesis of endothiopeptides via Ugi reaction.


































































































View Article Onlinecorrect. The antimicrobial activities of these amidines were
examined, but no activity was observed.
Based on the revised structures by Schipper26 and Kaneda,82
who proposed a cyclic tetrapeptide with a tripeptide chain
connected via an unusual amidine moiety, Kazmaier et al.
focused on the synthesis of the corresponding peptide ring and
the highly substituted amidine.83 A key step of their approach
was an Ugi reaction using a protected thioamino acid and NH3
as the amine compound (Scheme 2). Although Ugi reactions
with NH3 are oen non-specic and yield a range of side
products, good results were obtained with sterically demanding
aldehydes.84,85 With thiocarboxylic acids this approach allowed
the synthesis of endothiopeptides.86–88 With isocyanoacetate the
linear tripeptide 8 was obtained, which could be extended to the
desired tetrapeptide 9 under standard conditions. Attempts toScheme 3 Synthesis of amidine 13 via Ugi reaction.
Nat. Prod. Rep.cyclise 9 or to connect the side chain via peptide coupling failed,
because the thioamide underwent cyclisation to the thiazoli-
none 10, comparable to the imidazolone formation reported by
Yamada (Scheme 1).24
To gure out if amidine formation is possible between
sterically demanding amino acids, thiopeptide 11 was syn-
thesised in an analogous fashion (Scheme 3). Attempts to
couple 11 directly with amines failed, so the thioamide was
converted into the corresponding thioimidoester 12. In the
presence of Hg(OOCCF3)2 12 could be coupled with valine
methyl ester to obtain amidine 13 in good yield.
The diastereomers formed could be separated by ash
chromatography, but unfortunately this protocol could not be
carried out with endothiopeptide 8. This resulted in a change in
the strategy, replacing the intermolecular amidine formation
with an intramolecular one by using the isocyanide of tLeu-OMe
(Scheme 4). The endothiopeptide 14 was obtained in high yield
and could be extended on the N-terminus. S-Methylation and
cyclisation in the presence of Hg(OOCCF3)2 gave access to cyclic
amidine 15.
Amidine formation as the key step was also investigated in
detail by Ōmura and Sunazuka et al. during their synthesis of
bottromycin A2 (1a) and B2 (1b) (Scheme 5).78 They investigated
the reaction of thioamide 16 with the tripeptide side chain 17.
No reaction was observed in THF using NEt3 as a base, while in
the presence of Hg(OAc)2 the desired amidine 18 was not ob-
tained, and instead the amide 19 was produced. Better results
were obtained using HgCl2 and Hg(OTf)2 as Lewis acids. Finally,
2,6-lutidine in acetonitrile was the method of choice to yield 19.
The same groups also performed degradation studies of
bottromycin obtained by fermentation (Scheme 6).89 They sub-
jected 1a to pyrolysis in MeOH in a sealed tube at 130 C,Scheme 4 Synthesis of cyclic amidine 15 via Ugi reaction.
This journal is © The Royal Society of Chemistry 2021
Scheme 5 Synthesis of linear amidine 18.
Scheme 6 Degradation of bottromycin A2 (1a).
Scheme 7 Synthesis of tripeptide side chain 17.
Scheme 8 Total synthesis of bottromycin A2 (1a).


































































































View Article Onlineresulting in cleavage of the tripeptide side chain. Besides
dipeptide 20, cyclic product 21 was also obtained as a diaste-
reomeric mixture. Obviously, the epimerisation of the tLeu in
the side chain occurred via the enol-form of 21. This could
explain why the tLeu obtained by total hydrolysis of the bot-
tromycins has a lower optical rotation than the synthetic
enantiopure amino acid. Reduction under mild conditions
converted the natural product into alcohol 22, which could be
used to investigate cyclisation conditions.
Dipeptide 20 was also used to determine the conguration of
the thia-b-Ala, an amino acid that is rather congurational
labile.75 Both enantiomers of thia-b-Ala-OMe were synthesised
via the sulnamide protocol and subsequently coupled with
azido-MePhe 23 (Scheme 7). Reduction of the azido function-
ality of 24 provided the two diastereomeric dipeptides 20.
Comparison of their 1H NMR spectra with the spectrum of 20
obtained via pyrolysis clearly indicated that the (R)-isomer is
incorporated into the bottromycins and that the original
structure proposal (S) was incorrect. Coupling of 20 with Boc-
(S)-tLeu and subsequent Boc-cleavage provided tripeptide 17,This journal is © The Royal Society of Chemistry 2021which was also used in the amidine formation experiments
(Scheme 5).4.3 Total synthesis of bottromycin and analogs
Based on their own synthetic studies and with all building
blocks in hand, Sunazuka and Ōmura et al. developed the rst
and so far only complete total synthesis of bottromycin (Scheme
8).10,78 To extend the peptide chain, the Phth-group of amidine
18 was removed and the free amine was coupled with Boc-(S)-
Val. Further elongation gave rise to hexapeptide 25, which was
subjected to desilylation and oxidation. These last two steps had
to be carried out on the stage of the hexapeptide, as attempts to
oxidise tetrapeptide 18 resulted in the formation of a diketopi-
perazine. The oxidation was a very critical step due to the
nucleophilicity of the internal amidine. Thus all oxidation
methods proceeding via an aldehyde failed, because thisNat. Prod. Rep.
Scheme 9 Variable synthesis of 1a.
Scheme 11 Synthesis of bottromycin A2 analogs 34.


































































































View Article Onlinealdehyde intermediate was trapped by the amidine forming an
imidazole. Only Jones oxidation was successful, providing an
acceptable yield of the desired carboxylic acid 26. The amidine
was also problematic in the nal macrocyclisation step, and the
best results were obtained using EDCI/DIPEA in CH2Cl2,
although the yield of 1a was only moderate.
This protocol was also used to generate derivatives missing
some b-methyl groups, such as bottromycin B2 (1b) (Pro instead
of MePro), or derivatives where b-MePhe was replaced by Phe
[Phe-BotA2 (27), PheBotB2 (28)]. Their NMR spectra were rather
complicated (existence of conformers), which suggests that the
methyl group of the b-MePhe is important for the three-
dimensional structure of the bottromycins.Scheme 10 Synthesis of bottromycin A2 analogs 32.
Nat. Prod. Rep.Since it is known that the methyl ester of the thia-b-Ala has
an effect on the biological activity of bottromycins in vitro and in
vivo2 Sunazuka and Ōmura considered the synthesis of a bot-
tromycin derivative missing the C-terminal amino acid, so that
this position can be varied in the last step by coupling a wide
range of amines to the “shortened” hexapeptide. Although this
is a highly interesting approach, it was not as trivial as hoped.
Azido-MePhe 23 was converted into the corresponding benzyl
ester and, aer reduction of the azide, coupled to Boc-(S)-tLeu
(Scheme 9). The dipeptide 29 was incorporated into bot-
tromycin derivative 30 according to Scheme 9. The benzyl ester
could be cleaved easily to the carboxylic acid, the key interme-
diate for the synthesis of analogs. To validate the concept, the
acid was coupled with (R)-thia-b-Ala-OMe to the original natural
product 1a. The reaction proceeded smoothly, but 1a was only
a side product. The main product was derivative 31 containing
an imidazole on the tetrapeptide ring.
So far, HATU as the coupling reagent gave the best yields for
bottromycin A2 analogs (32) and was used to generate a range of
amides (Scheme 10), but the corresponding imidazole was the
main product in all cases.
Further bottromycin derivatives were obtained by saponi-
cation of the natural product 1a at the C-terminus and coupling
the free acid 33 with suitable nucleophiles (Scheme 11).
Researchers at AiCuris used this approach for the synthesis of
“Weinreb-amide”-type N-alkyl-N-alkoxyamides 34 by reaction
with linear or cyclic N,O-dialkylhydroxylamines (Table 2).90
The groups of Ōmura and Sunazuka synthesised a range of
different derivatives via the corresponding hydrazide 35 as
a common intermediate (Scheme 12).2 The hydrazide was easily
obtained by heating the solution of bottromycin A2 with
hydrazine. Nitrosation gave rise to acyl azide 36 as an active
intermediate, which could be coupled with a range of amines to
the corresponding amides 37. Application of mono Boc-
protected piperazine allowed further modication by replac-
ing the Boc-protecting group (38). On the other hand, heating
the acyl azide to 60 C resulted in a Curtius rearrangement that
gave rise to an isocyanate 39, which on treatment with amines
provided ureas 40. Reacting 36 with thiols gave rise to thioesters
such as 41 which could be subjected to palladium-catalysed
cross coupling reactions with organozinc reagents generating
ketones 42.
4.4 Biological activities and structure–activity relationship
(SAR) studies of bottromycins and derivatives
Based on the importance of the methyl ester for bioactivity and
its lability in vivo a range of amide derivatives 37 were prepared
and their in vitro and in vivo activity towards S. aureus (Table 3)This journal is © The Royal Society of Chemistry 2021
Scheme 12 Synthesis of bottromycin A2 analogs via hydrazine 35.
Table 3 Biological activities of bottromycins and C-terminal amide











1a 0.01 50 5000


































































































View Article Onlinewas compared.32 The tests were either carried out in vitro using
a rapid tube dilution test, or in an in vivo mouse model, where
compounds were administered intraperitoneally once. All
compounds were active, but the primary and secondary amides
were less active than the esters in the in vitro test, but more
active in vivo. Aromatic amides (37k–m) and those with a basic
substituent (37n) were less active to almost inactive in vivo, andTable 2 Synthesis of bottromycin analogs 34
34 R1 R2 R3 Yield (%)
34a Me Me Me 70
34b Me –(CH2)3– 40
34c Me –(CH2)4– 35
34d H –(CH2)4– 14
34e Me Et Et 50
34f Me Me Et 47
34g Me –CH2–CHOH–CH2– 63
34h Me –(CH2)3–CH(COOEt)– 52
34i Me –(CH2)3–CH(COOEt)– 84
34k Me 90
1b 0.04 200 5000
37a H H 0.10 25 250
37b Me H 0.05 10 200
37c Et H 0.05 15 300
37d nPr H 0.5 10 20
37e iPr H 1.0 10 10
37f tBu H 0.25 10 40
37g Bn H 0.5 18 36
37h CH2CHOHCH2OH H 1.0 25 25
37i CH2CH2OH H 0.5 18 36
37k Ph H 60
37l p-F-C6H4 >100
37m a-Naphthyl H >100
37n NH(CH2)2NEt3 H >100
37o iPr iPr 82
37p –CH2CH2CH2CH2– 95
37q NMe2 H 35
37r Me OH 28
35 NH2 H 46
This journal is © The Royal Society of Chemistry 2021 Nat. Prod. Rep.
Table 4 Biological activities of bottromycin hydroxamate derivatives











34a 0.78 <0.05 0.39 0.78
34c 0.39 <0.05 0.1 0.39
34d 3.13 <0.05 0.39 1.56


































































































View Article Onlinetertiary amides (37o,p) were also signicantly less active, while
hydrazides (35, 37q) and hydroxamates (37r) were relatively
active in vivo.
In a patent, researchers at AiCuris described the synthesis of
N,O-dialkylated bottromycin hydroxamates 34a–k (Table 2) and
their biological evaluation (Table 4).90
By far the most detailed SAR studies were reported by Ōmura
and Sunazuka, who also investigated the desmethyl derivatives
27 and 28, which were obtained by total synthesis (Scheme 8). A
wide range of different derivatives such as amides 32 (Scheme
12), 37 and 38, hydrazide 35, ureas 40, thioester 41 and ketones
42 were prepared from bottromycins obtained by fermentation



















33 Me H 64 64 64
35 16 16 16
37g Bn H 8 8 8
37s CH2CCH H 8 8 8
37t –(CH2)2O(CH2)2– 16 8 16
37u –(CH2)2SCH2– 4 4 8
37v –(CH2)2S(CH2)2– 8 4 8
38a Boc H 8 4 8
38b H 64 32 64
38c CH2CCH 16 16 16
38d Bn 4 4 4
40a –(CH2)2SCH2– 4 4 4
40b Bn 8 16 16
41 <0.25 0.5 <0.25
42a Et 1 1 2
42b nPr 1 1 1
VCMd 1 1 0.5
LZDe 2 2 2
a S. aureus FDA209P and Smith: susceptible strains. b MRSAHH-1 and 92-1
Enterococcus faecalis NCTC12201 and NCTC12203: encoded by vanA gene.
Nat. Prod. Rep.positive strains, using vancomycin (VCM) and linezolid (LZD) as
references (Table 5).2,78 The results of the SAR studies are
summarised schematically in Fig. 3.
The unusual methylation pattern (cyan) has a signicant
effect on the bioactivity towards S. aureus. Bottromycin D (1d),
where the valine is replaced by an alanine, and bottromycin B2
(1b), which does not have the methyl group at the proline, were
less active than bottromycin A2 (1a) (Tables 2 and 5).22 Bot-
tromycin C2 (1c), the analog dimethylated on proline, was
roughly as active as bottromycin A2. The b-methyl group on the
Phe seems to be essential and its removal (27, 28) causes
a dramatic drop in activity (Table 5). It appears that this methyl
group inuences the conformation of the side chain and
controls the three-dimensional structure of the whole molecule,
an assumption which is supported by 1H NMR.10,78 Bicyclic
derivatives such as 31 and linear peptides do not show signi-
cant activity, probably due to an undesired three dimensional
conformation, which clearly indicates that the cyclic peptide
ring (red) is essential.78 No activity was observed for derivatives
with either a COOH-group at the C-terminus, such as 33, or if
the thia-b-Ala is missing completely. This might be caused by
a drop in the hydrophobicity. Interestingly, incorporating the




















128 128 32 —
32 8 4 86
8 8 2 71
16 4 2 100
32 16 4 100
8 8 2 100
8 4 4 100
8 8 4 42
128 32 32 —
32 16 16 67
4 4 4 84
4 4 2 100
16 8 4 100
0.5 <0.25 <0.25 0
2 2 1 100
2 2 0.5 100
1 >128 >128 —
2 2 2 —
191: MRSA strains isolated from clinical patients. c Vancomycin resistant
d Vancomycin. e Linezolid.
This journal is © The Royal Society of Chemistry 2021
Fig. 3 Summary of SAR for bottromycin derivatives.


































































































View Article Onlineon activity (2 mg mL1). The thia-b-Ala (purple) was not essential
at all for activity – derivatives missing the acetate side chain
(32c) or the thiazole unit (32b) were only slightly less active.
Surprisingly benzyl amide 32d is almost as active as 1a, while
the corresponding benzyl ester 30 is not very effective. The dataFig. 4 Identification of the bottromycin BGC. (A) Organisation of the
identified in the S. sp. WMMB272 study as this BGC was at the end of
bottromycin BGC identified bioinformatically (all are Streptomyces spec
residues are shown with a light grey background (Risler matrix score >0.7
the conversion of the BotA precursor peptide into bottromycin A2, wh
product.
This journal is © The Royal Society of Chemistry 2021showed that the amide functionality (blue) is necessary for good
activities. Benzyl amide 32d is more active than the dethiazolyl
analog 32b, which indicates that an (hetero)aromatic substit-
uent at the C-terminus has a positive effect on activity. The
moderate in vivo activity of the methyl ester in the natural
products probably results from its low hydrolytic stability under
physiological conditions and its cleavage towards the almost
inactive carboxylic acid 33. Although signicantly less active in
vitro, better in vivo stabilities were observed for secondary
aliphatic amides (Table 3, 37a-i), while aromatic (37j–m) and
tertiary amides (37o,p) as well as those with basic side chains
(37n) were almost inactive.32 Piperazino derivatives 38 and ureas
40 exhibited 4- to 32-fold weaker activity in vitro, but better
stability.2 Thioesters such as 41 were signicantly more active
than 1a, but due to their great reactivity completely unstable in
mouse plasma. Ketones 42, which cannot undergo hydrolysis,
are perfectly stable and showed activities comparable to 1a andBGC. Gene nomenclature from each strain is shown (* ¼ genes not
a contig). (B) Sequence alignment of precursor peptides from every
ies). Identical residues are shown with a dark grey background, similar
) and the core peptide is highlighted in red text. (C) Schematic showing
ere all post-translational modifications are coloured red in the final
Nat. Prod. Rep.


































































































View Article Onlinevancomycin, but importantly were also active against
vancomycin-resistant strains. Subsequent biological evaluation
using MRSA-infected mice showed that propyl ketone 42b
might be a good candidate for drug development. 100 mg kg1
given to mice orally resulted in survival for at least ve days aer
administration, while all non-treated animals died in the same
time frame. Hydroxamates 34 (Table 4) might also be suitable
for this purpose.905 Biosynthetic gene cluster and
biosynthesis
The biosynthetic origin of the bottromycins was unknown for
decades following their discovery. They could feasibly be syn-
thesised via either ribosomal or non-ribosomal pathways, as all
residues could theoretically be produced from proteinogenic
amino acids. Early studies of bottromycin biosynthesis involved
elegant isotope labelling experiments from Arigoni and
colleagues, where it was shown that the methyl groups at the b-
positions of proline, two valines and phenylalanine, along with
the thia-b-Ala-OMe, were derived from methionine.91 They also
showed that b-methylated valine and phenylalanine derive from
L-valine and L-phenylalanine. Feeding S. bottropensis with
methionine featuring an isotopically labelled chiral methyl
group ([methyl-(2H,3H)]-(2S,methyl-R)-methionine) showed that
the b-methylation occurs with a retention of conguration. This
was consistent with double inversion of conguration via
a radical SAM mechanism.92 Additional experiments using
isotopically labelled amino acids were also consistent with
a radical SAM mechanism.91
In 2012, four independent research teams identied bot-
tromycin biosynthetic gene clusters (BGCs) in four different
Streptomyces species: the known producers S. bottropenesis11
and Streptomyces sp. BC16019,8 the plant pathogen Streptomyces
scabies6 and the marine ascidian-derived Streptomyces sp.
WMMB272 12 (Fig. 4A). These reports corroborated the earlier
feeding studies by showing that bottromycins are ribosomally
synthesised and post-translationally modied peptides
(RiPPs)15 and that the BGCs encode three radical SAM methyl-
transferases. In each study, the BGC was identied by BLAST
searches for genes that could encode a putative bottromycin
core peptide, GPVVVFDC (or GPAVVFDC for bottromycin D in S.
sp. WMMB272) (Fig. 4B). RiPPs originate from a larger riboso-
mally synthesised precursor peptide that usually consists of
a leader peptide and a core peptide that is post-translationally
modied by tailoring enzymes. However, the discovery of the
bottromycin BGC provided the rst (and still only) example of
a bacterial RiPP that derives from an N-terminal core peptide
that has no leader peptide and is attached to a “follower”
peptide (Fig. 4C).
The genetic organisation of these BGCs is effectively iden-
tical, and while there are signicant differences in protein
sequence identity between each BGC, S. sp. BC16019 nomen-
clature will be used here onwards for clarity. The bottromycin
BGC encodes 13 proteins (Fig. 4A): one precursor peptide
(BotA), two YcaO-domain proteins (BotC and BotCD), threeNat. Prod. Rep.radical SAM methyltransferases (BotRMT1-3), three putative
hydrolases (BotH, BotAH, BotP), one cytochrome P450 (Bot-
CYP), one O-methyltransferase (BotOMT), one putative regula-
tory protein (BotR) and one major facilitator superfamily
transporter (BotT). These initial studies revealed a number of
key details relating to bottromycin biosynthesis. Gene inacti-
vation experiments in S. bottropenesis,11 S. scabies6 and S. sp.
BC16019 8 conrmed the identity of the BGC, which was further
validated by heterologous expression of the S. sp. BC16019 BGC.
The identity of the BGC in S. sp. WMMB272 was demonstrated
by the production of bottromycin A2 upon expression of
a mutant precursor peptide gene that encoded the bottromycin
A2 core peptide instead of the natural bottromycin D core
peptide.12
Notably, gene deletions in the S. scabies BGC6 and insertional
inactivation of genes in the S. sp. BC16019 BGC8 demonstrated
the roles of the radical SAM methyltransferases BotRMT1-3 via
the production of differentially methylated bottromycin deriv-
atives by each mutant, thereby validating the earlier isotopic
labelling studies.91 BotRMT1 catalyses radical C-methylation of
Phe6, BotRMT2 catalyses radical C-methylation of both Val4
and Val5, and BotRMT3 catalyses radical C-methylation of Pro2.
At the time, this represented one of the rst examples of radical
b-methylation of amino acid residues, along with the poly-
theonamides, 49-amino acid RiPPs produced by ‘Candidatus
Entotheonella factor’, a member of a marine sponge micro-
biome.93 Multiple non-ribosomal peptides contain b-methyl-
ated amino acids, but these are generated via conventional
methylation of a precursor keto acid.94 Inactivation of botOMT
in the S. sp. BC16019 BGC conrmed its role in O-methylation
of Asp78. However, little else was known about the biosynthetic
steps required to convert BotA into mature bottromycin,
although plausible routes were initially proposed based on the
predicted catalytic roles of bot proteins. In-frame gene deletions
in the S. scabies BGC had demonstrated the essentiality of
numerous putative biosynthetic genes,6 including botC and
botCD (encoding the two YcaO-domain proteins), and botCYP
(encoding a P450), but no bottromycin related metabolites
could be initially identied from these mutants. The challenge
with identifying molecules related to RiPPs following gene
deletions is that a pathway may “stall” if a key step is disrupted,
with the core peptide still attached to the leader/follower
peptide. This therefore is likely to undergo further degrada-
tion into a very short modied peptide that may be distantly
related to the nal product and therefore difficult to detect.
To improve the detection of bottromycin-related metabolites
from pathway mutants, Truman and co-workers used mass
spectrometry-based molecular networking95 and untargeted
metabolomics to study in-frame deletions of orthologues of
botA, botC, botCD, botAH, botRMT1, botRMT2 and botCYP in S.
scabies.96 This analysis identied a series of bottromycin-related
molecules (intermediates or shunt metabolites) associated with
each mutant strain, which were then used to propose a feasible
pathway based on where the pathway stalled (Fig. 5). This
indicated that radical methylation by BotRMT1 and BotRMT2
were early steps in the pathway in S. scabies, as was hetero-
cyclisation of Cys8 by the standalone YcaO-domain proteinThis journal is © The Royal Society of Chemistry 2021
Fig. 5 Key metabolites identified by mutational analysis of bot biosynthetic genes. (A) Structures of metabolites based on tandem MS data from
Crone et al. (B) Proposed roles of biosynthetic proteins based on the studies of Crone et al.6 and Huo et al.8
Fig. 6 (A) BotP substrate promiscuity using pentapeptide mimics of
BotA with amino acid changes in P10position. (B) Model of BotP-Mn2+
(cyan) with the peptide MGPV (yellow).


































































































View Article OnlineBotC. Additionally, this study showed that the M17-family
leucine aminopeptidase BotP removes methionine from the
N-terminus of BotA.
Following removal of the N-terminal methionine by BotP, the
unique macrocyclic amidine of bottromycin was proposed to be
formed by BotCD (YcaO-domain protein) and BotAH (hydro-
lase), based on the production of linear bottromycin-related
peptides by each mutant (Fig. 5). Deletion of botCYP led to the
accumulation of O-desmethyl bottromycins A2 and B2 carbox-
ylated at their C-termini. This was consistent with BotCYP cat-
alysing late-stage oxidative decarboxylation of the thiazoline
moiety to generate a terminal thiazole. Each compound mass
appeared as twin peaks via liquid chromatography -mass
spectrometry (LC-MS), suggesting a mixture of aspartate
epimers, which was supported by deuterium labelling and
therefore provided a potential route to D-aspartate in mature
bottromycin. Epimerisation was shown to happen spontane-
ously, but it was not clear whether other proteins were involved
in accelerating this key step. No mutant strains produced
metabolites that are O-methylated on Asp7. This suggested that
O-methylation is the nal biosynthetic step, and it was shown
that puried BotOMT could methylate O-desmethyl bot-
tromycin A2. This was in agreement with the earlier gene inac-
tivation work by Huo et al.8
6 Biosynthetic enzymes
The following paragraphs will be dedicated to the enzymes
involved in the biosynthesis of the bottromycin core scaffold
(desmethyl bottromycin): BotP, BotC, BotCD, BotAH, BotH, and
BotCYP. The activity of these enzymes has been reconstituted in
vitro, and structural information is available for several of them.
Although the enzymes were studied using enzyme homologues
from different BGC containing Streptomyces species (see Fig. 4B),
the S. sp. BC16019 nomenclature will be used for clarity.
6.1 Aminopeptidase BotP
The aminopeptidase BotP belongs to the family of hexameric
M17 leucine aminopeptidases (LAP). LAPs are metallo-This journal is © The Royal Society of Chemistry 2021exopeptidases found in all kingdoms of life and cleave N-
terminal residues from proteins and peptides. They do not
only hydrolyse N-terminal leucine residues, but oen are
promiscuous. The function of LAPs is diverse and goes beyond
the function of recycling amino acids and includes the pro-
cessing of bioactive peptides and peptides for major histo-
compatibility complex (MHC) class I antigen presentation, gene
regulation and vesicular trafficking.97,98Nat. Prod. Rep.
Fig. 7 Biosynthetic pathway for bottromycin A2.


































































































View Article OnlineUsually, N-terminal methionine is hydrolysed by endoge-
nous aminopeptidases, but these do not function efficiently
with the MGP sequence found at the N-terminus of BotA.99 TheNat. Prod. Rep.aminopeptidase BotP was predicted6,8 and conrmed96,100 to
remove the N-terminal methionine from the precursor peptide
BotA (43), which generates the free glycine amino group (44)
(Fig. 7) that is necessary for the cyclisation onto an internal
amide carbonyl to generate the unique amidine macrocycle
found in bottromycins.
Koehnke and coworkers determined the crystal structure of
BotP (Fig. 6B) and assessed the substrate promiscuity of BotP
using pentapeptide mimics of BotA (Fig. 6A).100 BotP showed
a hexameric structure typical for M17 LAPs and the activity of
recombinant BotP, isolated from E. coli, could be reconstituted
in presence of Co2+ (or Mn2+) ions. RiPP enzymes catalysing the
initial biosynthetic steps oen bind to the follower (or for other
RiPPs leader) peptide to aid substrate recognition and enzyme
activity.101 For BotP modelling suggests that only the rst 3–4
amino acids contribute to substrate binding, but an in vitro
assay using pentapeptides showed that these truncated
substrates were processed slower than full-length BotA. The
reasons for this discrepancy remain to be determined. BotP
tolerates several amino acid changes in P1-P30, but processing is
reduced drastically.6.2 YcaO domain enzymes BotC and BotCD
The bottromycin biosynthetic gene cluster contains two genes
encoding for YcaO-domain enzymes, BotC and BotCD.6,8,11,12
YcaO proteins can be found in bacteria and archaea. Their
function is best characterised in RiPPs such as linear azol(in)e-
containing peptides (LAPs), thiopeptides and cyanobactins,
where the YcaO enzymes catalyse the ATP dependent cyclo-
dehydration reaction of Cys, Ser or Thr side chains onto the
preceding backbone amide carbonyl to form azoline heterocy-
cles.102–104 They can however also be used to generate non-
natural heterocycles.105,106
From an untargeted metabolomic approach it was predicted
that BotC catalyses the heterocyclisation of Cys to thiazoline
and BotCD, together with BotAH, catalyses the formation of the
unique macroamidine linkage.96 The function of the two bot-
tromycin YcaO enzymes were independently studied in in vitro
approaches by the Mitchell and Koehnke groups.107,108 It was
demonstrated that BotC catalyses the heterocyclisation reaction
that converts the core peptide's Cys residue to a thiazoline. The
second YcaO enzyme, BotCD, was sufficient to catalyse macro-
amidine formation. Both proteins bind to the follower peptide,
but with low affinity.107 BotC and BotCD were quite tolerant to
changes in the core peptide sequence but recalcitrant to
changes of the nucleophile.107,108 BotC was unable to utilise Ser
or Thr instead of Cys to generate oxazolines.107 While the
turnover of all bottromycin biosynthetic enzymes has been
shown to be relatively fast, heterocyclisation by BotC was shown
to be slow and could be the rate limiting step of the pathway,
since BotCD strongly prefers a heterocyclised substrate for
macrocyclisation.108 In contrast to all other YcaO enzymes
studied to date, the BotCD reaction was shown to be reversible:
the enzyme catalysed amidine formation and ring opening,
both in an ATP and Mg2+-dependent fashion.108 Thus BotCD
expanded the catalytic scope of YcaO enzymes in RiPP pathwaysThis journal is © The Royal Society of Chemistry 2021
Fig. 8 Proposed mechanism for macroamidine formation by the YcaO domain enzyme BotCD.


































































































View Article Onlineto amidine formation, but also raised questions as to possible
partner proteins for BotCD, which may prevent ring opening.
Based on the biochemical data it was proposed that macro-
amidine formation proceeds analogously to heterocyclization:
aer nucleophilic attack of the N-terminal amino group onto
the amide carbon a hemiorthoamide intermediate is formed,
which is then ATP-dependent O-phosphorylated, followed by
subsequent phosphate elimination to form the macroamidine
(Fig. 8).6.3 Amidohydrolase BotAH
Analysis of the metabolomic network from S. scabies DbtmI
(botAH orthologue) and DbtmF (botCD orthologue) revealed two
new bottromycin related molecules, which could not be found
in S. scabies WT and that were not macrocyclised. From this
observation it was proposed that BotCD and BotAH are involved
in macrocyclisation.96 However, in vitro data showed that BotCD
is sufficient to catalyse macrocyclisation. Pfam-analysis clas-
sies the protein encoded by the gene botAH as a putative
metallo-dependent amidohydrolase. From its putative function
it was assumed that either BotAH, or the putative a/b hydrolase
BotH, catalyses the liberation of the modied core from the
follower peptide for the nal biosynthetic steps. The crystal
structure of the BotAH homologue PurAH conrmed the Pfam
prediction. When the role of BotAH was probed in vitro it wasFig. 9 Proposed mechanism of the follower peptide cleavage by the a
peptide substrate is shown in orange.
This journal is © The Royal Society of Chemistry 2021discovered that it cleaved the follower peptide off the hetero-
and macrocyclised core peptide, and a mechanism was
proposed (Fig. 9).109 As observed for BotP, the highest activity of
BotAH was observed aer addition of Co2+. This may explain
increasing bottromycin production levels in S. scabies by
supplementation of production medium with Co2+.7
The biosynthetic role of BotAH raised the question of whether
it could aid macrocyclisation by inuencing the equilibrium of
the BotCD reaction. Aer all, the activity of BotCDwas dependent
on the follower peptide (attached to the modied core peptide).
Indeed, when added to macrocyclisation reactions, BotAH's
activity precluded ring opening and pulled the macroamidine
formation equilibrium to the side of macrocyclised product.109 As
a result, BotAH can be viewed as a YcaO accessory protein, the
rst hydrolase for which such a function has been reported.
These observations also rationalise why the amidohydrolase is
essential for macroamidine formation in vivo.6.4 Atypical a/b hydrolase BotH
The function of the a/b hydrolase (ABH) BotH was not studied in
vivo by gene deletion experiments and remained unclear until
very recently. Enzymes of the a/b hydrolase family catalyse the
hydrolysis of (thio)ester and peptide bonds, but some members
have diverse functions, such as dehalogenases, dioxygenases
and decarboxylases.110,111midohydrolase AH. BotAH active side residues are shown in back, the
Nat. Prod. Rep.
Fig. 11 BotCYP catalyses the oxidative decarboxylation reaction of the
thiazoline in 48 to the thiazole found in the bottromycin core struc-
ture. The cytochrome P450 enzyme is stereoselective for the D-Asp
containing intermediate and thus provides stereochemical resolution
for the pathway.
Fig. 10 BotH-48 (A) and BotH-bottromycin A2 (B) complex structures.


































































































View Article OnlineBotH is annotated as an ABH, and its crystal structure
revealed a typical ABH fold, but the canonical Ser–His–Asp
catalytic triad residues, which the majority of the ABH family
members possess, is mutated (Ser to Phe, His to Ile) or missing
(Asp).112 Accordingly, no hydrolytic activity was detected for
BotH. Instead, the follower-cleaved intermediate 47 binds to the
large cavity of the designated BotH active site and in vitro
biochemical assays determined BotH to function, unexpectedly,
as the epimerase of the Asp residue found in bottromycins (1).112
Deuteron labelling experiments revealed, that the enzyme
catalyses the rapid epimerisation of L-Asp to D-Asp, and its back-
reaction (Fig. 7). The action of BotH leads to a mixture of 47 and
48, but provides a much greater abundance of the D-Asp con-
taining intermediate 48 than the spontaneous epimerization,
which proceeds a glacial speeds and favours 47. In the complex
crystal structure of BotH with 48, no potential catalytic residues
of BotH were in a reasonable distance of the substrate Asp Ca
proton. In addition, mutation of the core peptide Asp residue to
Ala or Asn prevented epimerisation, but not binding. Substitu-
tion of Asp with Glu still allowed epimerization, which led the
suggestion of substrate-assisted catalysis. BotH is the rst re-
ported ABH to catalyse peptide epimerisation.
In other RiPP pathways, epimerisation usually involves
radical SAM enzymes or a two-step dehydration–hydrogenation
process to generate D-alanine from L-serine.113–116 BotH is thus
the founding member of a group of atypical ABH enzymes that
may be able to epimerise amino acids post-translationally and
but also other secondary metabolites. Further, BotH binds the
pathway product bottromycin A2, but is not able to epimerise it.
The complex crystal structure of BotH and bottromycin A2 was
the rst crystal structure of any bottromycin (Fig. 10). The
resulting orthosteric inhibition of BotH by bottromycin A2 may
results in a biosynthetic feedback mechanism to prevent self-
poisoning.1126.5 Cytochrome P450 enzyme BotCYP
Thiazoles (and oxazoles) as heterocycles derived from cysteine
(or serine/threonine) are a common motif in RiPPs and are
associated with linear azol(in)e-containing peptides (LAPs),
cyanobactins, thiopeptides, and bottromycins. Thiazoline
oxidation is more frequently observed than oxazoline oxidation
and usually involves an FMN-dependent dehydrogenase.13,15 In
bottromycin biosynthesis the oxidative carboxylation of the C-
terminal thiazoline is catalysed by the P450 enzyme found inNat. Prod. Rep.the gene cluster.96 P450 enzymes are not very common in RiPP
pathways, although a recent large-scale survey of the RiPP
landscape identied1800 P450 genes associated with putative
RiPP BGCs.117 The handful of P450 enzymes that had been
characterized from RiPP biosynthetic pathways predominantly
catalysed amino acids hydroxylation,118–121 but other functions
had also been reported.120,122,123 The P450-catalyzed oxidative
decarboxylation of a heterocycle in RiPP biosynthesis had not
been investigated in vitro but recent work by the Koehnke group
demonstrated that BotCYP selectively acts on D-Asp containing
intermediate 48 (Fig. 11).117 Given the substrate-assisted
mechanism of BotH, this observation rationalizes why all
attempts to produce bottromycin analogs with residues other
than Asp/Glu were unsuccessful (Fig. 13). Without a D-amino
acid in core peptide position 7 the pathway stalls at the point of
oxidative decarboxylation. Unfortunately the crystal structure of
a close BotCYP homologue did not provide an answer as to how
this enzyme may provide stereochemical resolution for the
pathway. The reconstitution of this step has nevertheless
enabled the production of the bottromycin core scaffold, which
may aid the production of bottromycin analogs for bioactivity
testing in the future.
7 Heterologous production of
bottromycins and derivatives
Early studies on bottromycin benetted from large-scale
fermentation to aid with product isolation and character-
isation, such as a 3000 litre fermentation used by Waisvisz and
colleagues in 1957 to rst characterise bottromycin.1 However,
more recently, numerous groups have reported very low bot-
tromycin yields with laboratory-scale fermentations,8,9,96 which
has presented challenges for understanding bottromycin
biosynthesis and engineering the pathway to generate
derivatives.
7.1 Regulation of the bottromycin biosynthetic gene cluster
To identify the transcriptional organisation of the bot-
tromycin BGC, Vior et al.7 used 50-tag-RNA-seq in S. scabies.This journal is © The Royal Society of Chemistry 2021
Fig. 12 Overview of bottromycin BGC regulation and methods used genetically engineer the BGC. (A) Natural transcriptional start sites and
predicted terminators determined by Vior et al.7 The gene encoding the pathway-situated transcriptional modulator BtmL (BotR) is highlighted.
(B) Overview of cloning and engineering the Streptomyces sp. BC16019 BGC by Huo et al.8 and Horbal et al.9 (C) Overview of cloning and
engineering the Streptomyces scabies BGC by Eyles et al.14 showing selected examples of engineered BGCs. (D) Bottromycin production chart
adapted from Eyles et al.14 [Theo] ¼ theophylline induction concentration.


































































































View Article OnlineThis revealed transcriptional start sites preceding botRMT1
and botOMT (Fig. 12A), as well as an internal transcriptional
start site within botRMT1, which precedes the precursor
peptide gene, botA. This is hypothesised to increase expres-
sion of the precursor peptide in relation to the tailoring
enzymes. RT-PCR (reverse transcription - polymerase chain
reaction) and 50-RACE (rapid amplication of cDNA ends)
experiments were consistent with the 50-tag-RNA-seqThis journal is © The Royal Society of Chemistry 2021analysis, although inferred a possible additional transcrip-
tional start site before botT that was not detected by 50-tag-
RNA-seq. This study showed that the bottromycin BGC
does not encode a pathway-specic master regulator, and
instead encodes a regulatory protein, BotR, that specically
modulates the expression of botA but not other genes in the
BGC. The precise mechanism of BotR-mediated modulation
remains enigmatic, especially as no strong promoter activityNat. Prod. Rep.


































































































View Article Onlinecould be detected from the internal transcriptional start site
that precedes botA.7.2 Heterologous expression of the bot BGC
Huo et al. were the rst to express a bottromycin BGC in
a heterologous host.8 Here, a pOJ436-based124 cosmid library
from Streptomyces sp. BC16019 was screened for the intact bot
BGC. The resulting DG2 construct was then expressed in
Streptomyces albus J1074 and Streptomyces coelicolor A3(2) to
successfully produce bottromycin A2, although estimated
production levels (1–4 mg L1) were much lower than from the
native producer. This large construct was simplied by
removing a 16 kb fragment of non-bot genes from the 50-end of
the BGC. This was replaced with a kanamycin resistance gene
via Red/ET recombineering125 to generate cosmid DG2-kan
(Fig. 12B).
To increase production levels from DG2-kan, an approach
pioneered by Ochi and colleagues126,127 was employed. This
strategy involved obtaining rifampicin-resistant isolates that
contain mutations in the rpoB gene, which encodes the RNA
polymerase b-subunit. These rpoBmutations can enhance levels
of antibiotic production in Streptomyces without affecting
growth. Accordingly, bottromycin production was increased by
about 10-fold in rifampicin-resistant mutants of S. coelicolor-
DG2-kan. Huo et al. hypothesised that a limiting factor pre-
venting higher yields was a lack of bottromycin resistance in S.
coelicolor. The most likely self-immunity gene in the cluster is
botT, which encodes a major facilitator superfamily (MFS)
transporter.128 Therefore, to increase botT expression, the region
preceding the botT gene was replaced with the strong PermE*
promoter using Red/ET recombineering. This further increased
bottromycin production levels two-fold compared to the
rifampicin-resistant mutants.
Given that 11 bot biosynthetic genes (botRMT1-botP) are
present on a polycistronic operon,7 it should be possible to
engineer pathway regulation by simply changing the promoter
preceding botRMT1 and optionally modifying the promoter(s)
for botOMT and botT. Truman and colleagues used
transformation-associated recombination (TAR) cloning129,130 in
Saccharomyces cerevisiae (yeast) to directly capture the bot-
tromycin BGC from the genomic DNA of S. scabies DSM 41658.14
This used the yeast/E. coli shuttle vector pCAP01,129 which can
also integrate into actinobacterial genomes via the fC31
attachment site. The resulting vector, pCAPbtm, was introduced
into S. coelicolor M1146,131 but bottromycin was produced in
negligible amounts. Therefore, it was hypothesised that the
bottromycin BGC could be efficiently engineered to improve
productivity by use of homologous recombination in yeast. This
strategy involved introducing double-strand breaks in pCAPbtm
via restriction sites naturally found in the bottromycin BGC.
This fragmented BGC was then repaired using a combination of
double- and single-stranded DNA fragments to introduce new
genetic features in a marker-free way (Fig. 12C).14
This approach was used to generate a series of modied
pCAPbtm-derived plasmids that contained a variety of strong
promoters (PSF14, PhrdB, Paac3, PermE*) in front of botRMT1Nat. Prod. Rep.and botT, as well as rearranged the botA and botRMT1 genes. In
an effort to limit the potential toxicity of bottromycin over-
production, the botOMT gene was removed, as previous work
had shown that BotOMT-catalysed O-methylation is important
for bottromycin activity.2 To fully understand the metabolic
consequences of engineering regulation, the total productivity
of the pathway was assessed using LC-MS-based metabolomics
to detect multiple peptides derived from the bottromycin
pathway that likely resulted from incomplete biosynthesis and
subsequent hydrolysis of modied BotA. One surprising chal-
lenge was that BotRMT1 was inactive in all conditions tested,
which resulted in all molecules lacking a b-methyl group on
phenylalanine. Sequencing revealed no mutations to the gene
cluster in any of the constructed vectors, so to further control
expression levels, an inducible theophylline-dependent ribos-
witch132 was incorporated upstream of botRMT1. While this did
not lead to active BotRMT1, theophylline induction did lead to
the most productive heterologous expression system tested in
this study, which was 120 times more productive than heterol-
ogous expression of the wild type BGC, as well as producing
higher levels of bottromycin-related metabolites than the native
S. scabies producer (Fig. 12D).
The DG2-kan cosmid generated by Huo et al.8was used as the
basis for BGC engineering by Luzhetskyy and colleagues.9 DG2-
kan contains the bot BGC from Streptomyces sp. BC16019, and
this cosmid was expressed in Streptomyces lividans TK24 to yield
0.23 mg L1 bottromycin A2. To improve pathway productivity,
the BGC was initially engineered to replace the native promoters
of botOMT and botRMT1with strong promoters from a promoter
library previously generated by the Luzhetskyy group.133 The
selection of strong promoters initially led to S. lividans growth
problems, potentially caused by toxicity of the pathway to the
host. This was overcome by selecting for bottromycin-resistant
S. lividans mutants, which led to bottromycin A2 production
levels of up to 3-fold higher than a control strain.
As it can be difficult to predict the precise relationship
between promoter strength and pathway productivity,
a ‘random rational strategy’ was employed to further boost
yields from DG2-kan. Here, a library of bot BGCs was generated
that featured random synthetic promoters inserted between
botOMT and botRMT1. These random promoters were created
based on the consensus 35 and 10 sequences of the
ermEp1 134 promoter (Fig. 12B). Degenerate primers were then
used to randomise the sequences upstream, between and
downstream of these consensus sequences. These were then
introduced into the BGC using Red/ET cloning, and the
mutated cosmids were conjugated into S. lividans TK24.
Screening of 100 randomly selected strains harbouring mutated
BGCs (DG2-KmRandom, Fig. 12B) revealed that 10% produced
5–50 fold more bottromycin A2 than a control strain harbouring
unmodied DG2-kan. Quantitative RT-PCR (RT-qPCR) revealed
that the transcription from both promoters had increased in the
best producer, but that the strength for each promoter was very
different (1 : 59 ratio), which emphasises the benet of
screening a promoter library. Pathway productivity was further
increased by introducing this mutated BGC into the native
producer, Streptomyces sp. BC16019, which therefore containedThis journal is © The Royal Society of Chemistry 2021
Fig. 13 Mutationsmade to precursor peptide BotA and homologues in
other bottromycin BGCs.2,9,136 The characterised structure of
bottromycin M is shown.


































































































View Article Onlineone copy each of the wild type and mutated bot BGCs. This led
to a 37-fold increase in bottromycin production in relation to
wild type Streptomyces sp. BC16019.
There is a lack of natural diversity within the core peptides of
known bottromycins (Fig. 4B), which is in contrast to most
other RiPP families.15 RiPPs are uniquely suited to pathway
engineering to generate derivatives, as mutations to the core
peptide lead to predictable changes to the nal chemical
structure. The lack of diversity amongst natural bottromycins
means that there is a lot of chemical space to explore for
bottromycin-like molecules, which could be important in the
context of antibiotic discovery. Therefore, Luzhetskyy and
colleagues generated DG2-kan cosmids with mutated botA
genes,9 and then introduced these into Streptomyces sp.
BC16019 DbotA, which is unable to make the wild type BotA
precursor peptide. 12 mutants were generated, although most
led to no detectable bottromycin-like metabolites, indicating
a lack of pathway tolerance to these unnatural substrates, which
is unlike many other RiPP pathways.135 Based on these data, the
position most tolerant of modications was Val3 of the core
peptide (Fig. 13). Peptides with isoleucine and methionine
residues at this position were successfully converted into bot-
tromycin derivatives containing all expected post-translational
modications. Fig. 13 shows methionine-containing
bottromycin M. Position 3 of the core peptide is effectively the
only amino acid that is not post-translationally modied during
biosynthesis and is the only position where natural variation
has been observed, as bottromycin D from Streptomyces sp.
WMMB272 features an alanine at this position.12 In this strain,
an Ala3Val mutant was tolerated and therefore generated bot-
tromycin A2. In contrast, no products were detected from three
different mutants of Asp7 in this strain (Fig. 13).This journal is © The Royal Society of Chemistry 2021Comparable mutation results were obtained by Crone et al.136
Here, 22 botA mutants were generated using the precursor
peptide complementation strategy previously reported for S.
scabies DbtmD6 (the botA orthologue in this strain). As with
Streptomyces sp. BC16019, Val3 of the core peptide was most
tolerant of mutations, where mutations to Ala, Ile, Ser and Thr
residues all led to bottromycin analogs with expected masses
and tandem MS fragmentation patterns (Fig. 13). As with the
other mutant studies, no bottromycin analogs were produced by
mutations to Asp7, which was targeted due to the reported
importance of this residue for activity.
8 Conclusions
Over 60 years aer their original discovery bottromycins
continue to capture the attention of research groups and
provide riddles to be solved. Given the developing antibiotic
crisis and the effectiveness of bottromycins against (multi)
drug-resistant pathogens, the recent advances in bottromycin
research should be capitalized on: through chemical synthesis
and a combination of biochemistry/biotechnology new chem-
ical space has become available to explore a more comprehen-
sive SAR and address the in vivo instability of the compounds. In
addition, the actual target within the A-site of the prokaryotic
50S ribosome has remained elusive and the MICs of some
derivatives suggest an alternative, unknown target. We there-
fore think that despite its long history, the story of bottromycins
may be just beginning.
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T. Hirose, S. Ōmura and T. Sunazuka, Synthesis and
Evaluation of Antibacterial Activity of Bottromycins, J. Org.
Chem., 2018, 83(13), 7135–7149.
79 T. Yamada, K. Suegane, S. Kuwata and H. Watanabe,
Studies of unusual amino acids and their peptides. VII.
The syntheses and the reactions of iminopeptides, Bull.
Chem. Soc. Jpn., 1977, 50(5), 1088–1093.
80 S. Nakamura, T. Chikaike, H. Yonehara and H. Umezawa,
Structures of Bottromycins A and B, J. Antibiot., 1965, 18,
60–61.This journal is © The Royal Society of Chemistry 2021


































































































View Article Online81 S. Nakamura and H. Umezawa, The structure of
bottromycin A2, a new component of bottromycins, Chem.
Pharm. Bull., 1966, 14(9), 981–986.
82 M. Kaneda, Studies on bottromycins. I. 1H and 13C NMR
assignments of bottromycin A2, the main component of
the complex, J. Antibiot., 1992, 45(5), 792–796.
83 S. Ackermann, H.-G. Lerchen, D. Haebich, A. Ullrich and
U. Kazmaier, Synthetic studies towards bottromycin,
Beilstein J. Org. Chem., 2012, 8, 1652–1656.
84 U. Kazmaier and C. Hebach, Peptide syntheses via Ugi
reactions with ammonia, Synlett, 2003, 11, 1591–1594.
85 R. Pick, M. Bauer, U. Kazmaier and C. Hebach, Ammonia in
Ugi reactions - Four-component versus six-component
couplings, Synlett, 2005, 5, 757–760.
86 M. Bauer, F. Maurer, S. M. Hoffmann and U. Kazmaier,
Hydroxyalkyl Thiazolines, a New Class of Highly Efficient
Ligands for Carbonyl Additions, Synlett, 2008, (20), 3203–
3207.
87 U. Kazmaier and S. Ackermann, A straightforward approach
towards thiazoles and endothiopeptides via Ugi reaction,
Org. Biomol. Chem., 2005, 3(17), 3184–3187.
88 U. Kazmaier and A. Persch, A straightforward approach
towards 5-substituted thiazolylpeptides via the thio-Ugi-
reaction, Org. Biomol. Chem., 2010, 8(23), 5442–5447.
89 F. Hata, A. Matsumae, K. Abe, Y. Sano, M. Otani and
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A. M. C. Rodŕıguez, A. Lamsa, C. Zhang, K. Dorrestein,
B. M. Duggan, J. Almaliti, P.-M. Allard, P. Phapale,
L.-F. Nothias, T. Alexandrov, M. Litaudon, J.-L. Wolfender,
J. E. Kyle, T. O. Metz, T. Peryea, D.-T. Nguyen, D. VanLeer,
P. Shinn, A. Jadhav, R. Müller, K. M. Waters, W. Shi,
X. Liu, L. Zhang, R. Knight, P. R. Jensen, B. Ø. Palsson,
K. Pogliano, R. G. Linington, M. Gutiérrez, N. P. Lopes,
W. H. Gerwick, B. S. Moore, P. C. Dorrestein and
N. Bandeira, Sharing and community curation of mass
spectrometry data with Global Natural Products Social
Molecular Networking, Nat. Biotechnol., 2016, 34(8), 828–
837.
96 W. J. K. Crone, N. M. Vior, J. Santos-Aberturas,
L. G. Schmitz, F. J. Leeper and A. W. Truman, Dissecting
Bottromycin Biosynthesis Using Comparative Untargeted
Metabolomics, Angew. Chem., Int. Ed., 2016, 55(33), 9639–
9643.
97 M. Matsui, J. H. Fowler and L. L. Walling, Leucine
aminopeptidases: diversity in structure and function, Biol.
Chem., 2006, 387(12), 1535–1544.
98 S. Dorus, E. C. Wilkin and T. L. Karr, Expansion and
functional diversication of a leucyl aminopeptidase
family that encodes the major protein constituents of
Drosophila sperm, BMC Genomics, 2011, 12, 177.
99 F. Frottin, A. Martinez, P. Peynot, S. Mitra, R. C. Holz,
C. Giglione and T. Meinnel, The proteomics of N-terminal
methionine cleavage, Mol. Cell. Proteomics, 2006, 5(12),
2336–2349.
100 G. Mann, L. Huo, S. Adam, B. Nardone, J. Vendome,
N. J. Westwood, R. Müller and J. Koehnke, Structure and
Substrate Recognition of the Bottromycin Maturation
Enzyme BotP, ChemBioChem, 2016, 17(23), 2286–2292.
101 T. J. Oman and W. A. van der Donk, Follow the leader: the
use of leader peptides to guide natural product
biosynthesis, Nat. Chem. Biol., 2010, 6(1), 9–18.
102 S. W. Lee, D. A. Mitchell, A. L. Markley, M. E. Hensler,
D. Gonzalez, A. Wohlrab, P. C. Dorrestein, V. Nizet and
J. E. Dixon, Discovery of a widely distributed toxin
biosynthetic gene cluster, Proc. Natl. Acad. Sci. U. S. A.,
2008, 105(15), 5879–5884.Nat. Prod. Rep.


































































































View Article Online103 L. C.Wieland Brown, M. G. Acker, J. Clardy, C. T. Walsh and
M. A. Fischbach, Thirteen posttranslational modications
convert a 14-residue peptide into the antibiotic thiocillin,
Proc. Natl. Acad. Sci. U. S. A., 2009, 106(8), 2549–2553.
104 E. W. Schmidt, J. T. Nelson, D. A. Rasko, S. Sudek,
J. A. Eisen, M. G. Haygood and J. Ravel, Patellamide A
and C biosynthesis by a microcin-like pathway in
Prochloron didemni, the cyanobacterial symbiont of
Lissoclinum patella, Proc. Natl. Acad. Sci. U. S. A., 2005,
102(20), 7315–7320.
105 Y. Goto and H. Suga, In Vitro Biosynthesis of Peptides
Containing Exotic Azoline Analogues, ChemBioChem,
2020, 21(1–2), 84–87.
106 J. Koehnke, F. Morawitz, A. F. Bent, W. E. Houssen,
S. L. Shirran, M. A. Fuszard, I. A. Smellie, C. H. Botting,
M. C. M. Smith, M. Jaspars and J. H. Naismith, An
Enzymatic Route to Selenazolines, ChemBioChem, 2013,
14(5), 564–567.
107 C. J. Schwalen, G. A. Hudson, S. Kosol, N. Mahanta,
G. L. Challis and D. A. Mitchell, In Vitro Biosynthetic
Studies of Bottromycin Expand the Enzymatic
Capabilities of the YcaO Superfamily, J. Am. Chem. Soc.,
2017, 139(50), 18154–18157.
108 L. Franz, S. Adam, J. Santos-Aberturas, A. W. Truman and
J. Koehnke, Macroamidine Formation in Bottromycins Is
Catalyzed by a Divergent YcaO Enzyme, J. Am. Chem. Soc.,
2017, 139(50), 18158–18161.
109 A. Sikandar, L. Franz, O. Melse, I. Antes and J. Koehnke,
Thiazoline-Specic Amidohydrolase PurAH Is the
Gatekeeper of Bottromycin Biosynthesis, J. Am. Chem.
Soc., 2019, 141(25), 9748–9752.
110 J. T. Mindrebo, C. M. Nartey, Y. Seto, M. D. Burkart and
J. P. Noel, Unveiling the functional diversity of the alpha/
beta hydrolase superfamily in the plant kingdom, Curr.
Opin. Struct. Biol., 2016, 41, 233–246.
111 A. Rauwerdink and R. J. Kazlauskas, How the Same Core
Catalytic Machinery Catalyzes 17 Different Reactions: the
Serine-Histidine-Aspartate Catalytic Triad of a/b-
Hydrolase Fold Enzymes, ACS Catal., 2015, 5(10), 6153–
6176.
112 A. Sikandar, L. Franz, S. Adam, J. Santos-Aberturas,
L. Horbal, A. Luzhetskyy, A. W. Truman, O. V. Kalinina
and J. Koehnke, The bottromycin epimerase BotH denes
a group of atypical a/b-hydrolase-fold enzymes, Nat.
Chem. Biol., 2020, 16, 1013–1018.
113 B. I. Morinaka, A. L. Vagstad, M. J. Helf, M. Gugger,
C. Kegler, M. F. Freeman, H. B. Bode and J. Piel, Radical
S-Adenosyl Methionine Epimerases: Regioselective
Introduction of Diverse D-Amino Acid Patterns into
Peptide Natural Products, Angew. Chem., Int. Ed., 2014,
53(32), 8503–8507.
114 A. Benjdia, A. Guillot, P. Ruffié, J. Leprince and O. Berteau,
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Understanding transport by the major facilitator
superfamily (MFS): structures pave the way, Nat. Rev. Mol.
Cell Biol., 2016, 17(2), 123–132.
129 K. Yamanaka, K. A. Reynolds, R. D. Kersten, K. S. Ryan,
D. J. Gonzalez, V. Nizet, P. C. Dorrestein and B. S. Moore,
Direct cloning and refactoring of a silent lipopeptide
biosynthetic gene cluster yields the antibiotic taromycin
A, Proc. Natl. Acad. Sci. U. S. A., 2014, 111(5), 1957–1962.
130 V. Noskov, N. Kouprina, S.-H. Leem, M. Koriabine,
J. C. Barrett and V. Larionov, A genetic system for direct
selection of gene-positive clones during recombinational
cloning in yeast, Nucleic Acids Res., 2002, 30(2), e8.
131 J. P. Gomez-Escribano and M. J. Bibb, Engineering
Streptomyces coelicolor for heterologous expression of
secondary metabolite gene clusters, Microb. Biotechnol.,
2011, 4(2), 207–215.This journal is © The Royal Society of Chemistry 2021132 M. M. Rudolph, M.-P. Vockenhuber and B. Suess, Synthetic
riboswitches for the conditional control of gene expression
in Streptomyces coelicolor, Microbiology, 2013, 159, 1416–
1422.
133 T. Siegl, B. Tokovenko, M. Myronovskyi and A. Luzhetskyy,
Design, construction and characterisation of a synthetic
promoter library for ne-tuned gene expression in
actinomycetes, Metab. Eng., 2013, 19, 98–106.
134 W. R. Strohl, Compilation and analysis of DNA sequences
associated with apparent streptomycete promoters,
Nucleic Acids Res., 1992, 20(5), 961–974.
135 G. A. Hudson and D. A. Mitchell, RiPP antibiotics:
biosynthesis and engineering potential, Curr. Opin.
Microbiol., 2018, 45, 61–69.
136 W. J. K. Crone, Investigations into the biosynthesis of
bottromycin, University of Cambridge Cambridge, 2015.Nat. Prod. Rep.
